Symbols / ACXP
ACXP Chart
About
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia; and CCP, multiple product candidates for gram-positive infections. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 4.05M |
| Enterprise Value | -2.45M | Income | -9.17M | Sales | — |
| Book/sh | 2.02 | Cash/sh | 2.83 | Dividend Yield | — |
| Payout | 0.00% | Employees | 4 | IPO | — |
| P/E | — | Forward P/E | -0.43 | PEG | — |
| P/S | — | P/B | 0.79 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 2.41 |
| Current Ratio | 2.47 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -8.18 | EPS next Y | -3.71 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-13 | ROA | -95.64% |
| ROE | -291.06% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 2.55M |
| Shs Float | 1.98M | Short Float | 2.80% | Short Ratio | 1.28 |
| Short Interest | — | 52W High | 21.00 | 52W Low | 1.58 |
| Beta | -1.22 | Avg Volume | 58.15K | Volume | 48.58K |
| Target Price | $61.70 | Recom | None | Prev Close | $1.66 |
| Price | $1.59 | Change | -4.22% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$61.70
Mean price target
2. Current target
$1.59
Latest analyst target
3. DCF / Fair value
$-34.47
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.59
Low
$20.00
High
$165.80
Mean
$61.70
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-30 | reit | HC Wainwright & Co. | Buy → Buy | $31 |
| 2025-08-12 | main | HC Wainwright & Co. | Buy → Buy | $31 |
| 2025-03-19 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-01-13 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-01-10 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-12-10 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-08-12 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-05-16 | reit | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-03-19 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2024-02-28 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2023-12-15 | main | HC Wainwright & Co. | Buy → Buy | $14 |
| 2023-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2023-09-13 | reit | HC Wainwright & Co. | Buy → Buy | $13 |
| 2023-08-15 | main | HC Wainwright & Co. | Buy → Buy | $13 |
| 2023-05-15 | reit | HC Wainwright & Co. | Buy → Buy | $14 |
| 2023-04-11 | reit | HC Wainwright & Co. | — → Buy | $14 |
| 2023-03-17 | reit | HC Wainwright & Co. | — → Buy | $14 |
| 2022-12-19 | init | HC Wainwright & Co. | — → Buy | $14 |
| 2022-10-20 | init | Alliance Global Partners | — → Buy | $14 |
- Acurx Pharmaceuticals (ACXP) Secures New US Patent for DNA Polymerase IIIC Inhibitors - Yahoo Finance ue, 24 Feb 2026 18
- Acurx patent backs new antibiotics for C. diff and MRSA - Stock Titan Mon, 02 Feb 2026 08
- 90% Plunge to 1000% Upside? Acurx Pharmaceuticals (ACXP) Stock Sees EMA Boost & Bold Analyst Predictions - TechStock² Wed, 08 Oct 2025 07
- Acurx Approves 1-for-20 Reverse Stock Split To Regain Nasdaq Compliance - Nasdaq hu, 31 Jul 2025 07
- Earnings call transcript: Acurx Pharmaceuticals Q2 2025 misses EPS forecast - Investing.com ue, 12 Aug 2025 07
- Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors - Stock Titan hu, 09 Oct 2025 07
- Pharma Boom: Acurx on the Rise - StocksToTrade Wed, 08 Oct 2025 07
- ACXP’s Steady Climb: New Developments? - timothysykes.com Wed, 08 Oct 2025 07
- MAGA Stocks Undercard: MYSE, XBIO, ATON, ACXP, RDZN - Innovators Driving Next Tech, Blockchain, AI Wave - More Stocks Inside - marketscreener.com hu, 09 Oct 2025 07
- Has Acurx Pharmaceuticals (ACXP) Outpaced Other Medical Stocks This Year? - Yahoo Finance ue, 06 Jan 2026 08
- Acurx Pharmaceuticals, Inc. SEC 10-Q Report - TradingView Wed, 12 Nov 2025 08
- Acurx's ibezapolstat shows microbiome-sparing properties in trials By Investing.com - Investing.com Nigeria ue, 28 Oct 2025 07
- Biotech Acurx Pharmaceuticals Raises $2.67M in Strategic Warrant Exercise - New Warrants Issued at $0.425 - Stock Titan ue, 17 Jun 2025 07
- Acurx Pharma Q3 net loss narrows to $2 mln - TradingView Wed, 12 Nov 2025 08
- Earnings call transcript: Acurx Pharmaceuticals Q3 2025 reveals cautious outlook - Investing.com Wed, 12 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 24631 | 25000 | — | Purchase at price 1.02 per share. | SCODARI JOSEPH C | Director | — | 2025-01-06 00:00:00 | D |
| 1 | 49261 | 50000 | — | Purchase at price 1.02 per share. | DELUCCIA ROBERT J | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-01-06 00:00:00 | D |
| 2 | 49261 | 50000 | — | Purchase at price 1.02 per share. | LUCI DAVID P | Chief Executive Officer | — | 2025-01-06 00:00:00 | D |
| 3 | 9852 | 10000 | — | Purchase at price 1.02 per share. | DEAN JACK H | Director | — | 2025-01-06 00:00:00 | D |
| 4 | 9852 | 10000 | — | Purchase at price 1.02 per share. | DONOHUE JAMES J. | Director | — | 2025-01-06 00:00:00 | D |
| 5 | 24631 | 25000 | — | Purchase at price 1.02 per share. | SAILER CARL | Director | — | 2025-01-06 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -14.10M | -14.58M | -12.09M | -12.88M |
| TotalUnusualItems | 0.00 | 66.50K | ||
| TotalUnusualItemsExcludingGoodwill | 0.00 | 66.50K | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -14.10M | -14.58M | -12.09M | -12.75M |
| EBITDA | -14.10M | -14.58M | -12.09M | -12.81M |
| EBIT | -14.10M | -14.58M | -12.09M | -12.81M |
| NormalizedIncome | -14.10M | -14.58M | -12.09M | -12.81M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -14.10M | -14.58M | -12.09M | -12.75M |
| TotalExpenses | 14.10M | 14.58M | 12.09M | 12.81M |
| DilutedAverageShares | 808.17K | 633.58K | 540.82K | 426.79K |
| BasicAverageShares | 808.17K | 633.58K | 540.82K | 426.79K |
| DilutedEPS | -17.40 | -23.00 | -22.40 | -29.80 |
| BasicEPS | -17.40 | -23.00 | -22.40 | -29.80 |
| DilutedNIAvailtoComStockholders | -14.10M | -14.58M | -12.09M | -12.75M |
| NetIncomeCommonStockholders | -14.10M | -14.58M | -12.09M | -12.75M |
| NetIncome | -14.10M | -14.58M | -12.09M | -12.75M |
| NetIncomeIncludingNoncontrollingInterests | -14.10M | -14.58M | -12.09M | -12.75M |
| NetIncomeContinuousOperations | -14.10M | -14.58M | -12.09M | -12.75M |
| PretaxIncome | -14.10M | -14.58M | -12.09M | -12.75M |
| OtherIncomeExpense | 66.50K | |||
| SpecialIncomeCharges | 0.00 | 66.50K | ||
| OtherSpecialCharges | -66.50K | |||
| OperatingIncome | -14.10M | -14.58M | -12.09M | -12.81M |
| OperatingExpense | 14.10M | 14.58M | 12.09M | 12.81M |
| ResearchAndDevelopment | 5.40M | 6.04M | 4.75M | 2.03M |
| SellingGeneralAndAdministration | 8.70M | 8.53M | 7.34M | 10.78M |
| GeneralAndAdministrativeExpense | 8.70M | 8.53M | 7.34M | 10.78M |
| OtherGandA | 8.70M | 8.53M | 7.34M | 10.78M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 851.53K | 723.41K | 581.38K | 510.79K |
| ShareIssued | 851.53K | 723.41K | 581.38K | 510.79K |
| TangibleBookValue | 615.12K | 4.67M | 7.32M | 12.41M |
| InvestedCapital | 615.12K | 4.67M | 7.32M | 12.41M |
| WorkingCapital | 615.12K | 4.67M | 7.32M | 12.41M |
| NetTangibleAssets | 615.12K | 4.67M | 7.32M | 12.41M |
| CommonStockEquity | 615.12K | 4.67M | 7.32M | 12.41M |
| TotalCapitalization | 615.12K | 4.67M | 7.32M | 12.41M |
| TotalEquityGrossMinorityInterest | 615.12K | 4.67M | 7.32M | 12.41M |
| StockholdersEquity | 615.12K | 4.67M | 7.32M | 12.41M |
| GainsLossesNotAffectingRetainedEarnings | -38.64M | -26.55M | ||
| OtherEquityAdjustments | -38.64M | -26.55M | ||
| RetainedEarnings | -67.32M | -53.22M | -38.64M | -26.55M |
| AdditionalPaidInCapital | 67.92M | 57.87M | 45.94M | 38.95M |
| CapitalStock | 17.03K | 14.47K | 11.63K | 10.22K |
| CommonStock | 17.03K | 14.47K | 11.63K | 10.22K |
| TotalPartnershipCapital | -53.22M | -38.64M | ||
| TotalLiabilitiesNetMinorityInterest | 3.24M | 3.04M | 2.06M | 843.91K |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentLiabilities | 3.24M | 3.04M | 2.06M | 843.91K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 537.63K | 716.31K | 542.89K | 508.34K |
| PayablesAndAccruedExpenses | 2.71M | 2.33M | 1.52M | 335.57K |
| CurrentAccruedExpenses | 2.70M | 2.32M | 1.49M | 272.19K |
| Payables | 4.79K | 3.81K | 29.54K | 63.37K |
| OtherPayable | 4.79K | 3.81K | 29.54K | 63.37K |
| TotalAssets | 3.86M | 7.71M | 9.38M | 13.25M |
| TotalNonCurrentAssets | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 3.86M | 7.71M | 9.38M | 13.25M |
| PrepaidAssets | 100.12K | 105.78K | 264.95K | 295.30K |
| Receivables | 51.13K | 129.16K | 0.00 | |
| OtherReceivables | 51.13K | 129.16K | ||
| CashCashEquivalentsAndShortTermInvestments | 3.71M | 7.47M | 9.11M | 12.96M |
| CashAndCashEquivalents | 3.71M | 7.47M | 9.11M | 12.96M |
| CashFinancial | 3.71M | 7.47M | 9.11M | 12.96M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -10.38M | -9.80M | -7.54M | -5.01M |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 6.41M | 5.94M | 3.70M | 14.80M |
| EndCashPosition | 3.71M | 7.47M | 9.11M | 12.96M |
| BeginningCashPosition | 7.47M | 9.11M | 12.96M | 3.18M |
| ChangesInCash | -3.77M | -1.64M | -3.85M | 9.78M |
| FinancingCashFlow | 6.62M | 8.16M | 3.70M | 14.80M |
| CashFlowFromContinuingFinancingActivities | 6.62M | 8.16M | 3.70M | 14.80M |
| ProceedsFromStockOptionExercised | 210.20K | 2.22M | 13.00 | 0.00 |
| NetCommonStockIssuance | 6.41M | 5.94M | 3.70M | 14.80M |
| CommonStockIssuance | 6.41M | 5.94M | 3.70M | 14.80M |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtIssuance | 0.00 | |||
| OperatingCashFlow | -10.38M | -9.80M | -7.54M | -5.01M |
| CashFlowFromContinuingOperatingActivities | -10.38M | -9.80M | -7.54M | -5.01M |
| ChangeInWorkingCapital | 284.09K | 1.01M | 1.25M | 141.28K |
| ChangeInPayablesAndAccruedExpense | 200.40K | 980.75K | 1.22M | 387.98K |
| ChangeInPrepaidAssets | 5.65K | 159.18K | 30.35K | -246.69K |
| ChangeInReceivables | 78.03K | -129.16K | 0.00 | |
| OtherNonCashItems | 559.58K | 430.68K | 1.59M | |
| StockBasedCompensation | 3.44M | 3.77M | 3.30M | 6.74M |
| OperatingGainsLosses | 850.26K | |||
| PensionAndEmployeeBenefitExpense | 0.00 | 916.76K | ||
| NetIncomeFromContinuingOperations | -14.10M | -14.58M | -12.09M | -12.75M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ACXP
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|